Home > Riviste > Minerva Ginecologica > Fascicoli precedenti > Minerva Ginecologica 2014 April;66(2) > Minerva Ginecologica 2014 April;66(2):179-92

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

  FOCUS SUI DISTURBI OVARICI 

Minerva Ginecologica 2014 April;66(2):179-92

Copyright © 2014 EDIZIONI MINERVA MEDICA

lingua: Inglese

New paradigms in the surgical and adjuvant treatment of ovarian cancer

Hodeib M., Eskander R. N., Bristow R. E.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of California, Irvine, Orange, CA, USA


PDF


Advanced stage epithelial ovarian cancer is difficult to treat. Despite advances in surgical resection and adjuvant chemotherapy the majority of patients suffer from disease recurrence. In an effort to improve oncologic outcomes, including progression free and overall survival, novel surgical paradigms and chemotherapeutic techniques have emerged over the past decade. An emphasis has been placed on achieving maximal surgical cytoreduction (defined as no visible residual disease) at completion of surgery, in combination with intra-peritoneal (IP) chemotherapy, as well as hyperthermic IP chemotherapy (HIPEC). This review article will discuss the evolution of surgical cytoreduction in the treatment of advanced stage epithelial ovarian cancer, as well as the development of adjuvant treatments that increasingly utilize the biologic advantage provided by microscopic residual disease.

inizio pagina